Diagnostics & Genomics
I

Invitae

Invitae is a genetic testing brand owned by Labcorp, which acquired the business in 2024 after Invitae's bankruptcy. It keeps its own site and test menu and now presents itself as Invitae and Labcorp together, with some billing handled by Labcorp Genetics. It sells germline testing across oncology, women's health, pediatrics and rare disease, cardiology and neurology, ordered by clinicians and returned with genetic counseling at no additional cost, and reports more than five million patients tested.

The learned components are in variant interpretation. The Invitae Evidence Modeling platform, built in part on Invitae's 2020 acquisition of Jungla, trains gene specific machine learning models on curated evidence, keeps only models that pass accuracy thresholds, and calibrates their predictions so they can enter the Sherloc variant classification framework as one line of evidence that the laboratory's scientists weigh. A 2025 preprint by former Invitae scientists now at Labcorp reports the platform applied to more than 800,000 variants across a million people, 42 percent of which would otherwise have stayed variants of uncertain significance, with more than 99 percent agreement with later ClinVar submissions for definitive classifications. Moon, a machine learning tool for exome analysis, ranks the variants most likely to explain a patient's case.

Orders and results run through Epic's Aura network, and Labcorp reports more than 400 customer record integrations completed for genetic testing. Invitae publishes a HIPAA notice of privacy practices and a privacy policy, both dated before the Labcorp acquisition, and its licensing page states HITRUST CSF certification.

AI Health Index verifiedNovember 8, 2026
Compare Invitae with other vendors
Founded
2010
Headquarters
San Francisco, California, United States
Website
www.invitae.com
Categories
diagnostics-and-genomics
Indexed Products
Invitae germline genetic testing (oncology, women's health, pediatrics and rare disease, cardiology, neurology), Invitae Evidence Modeling platform, Moon exome analysis software, Genetic risk assessment, Post test genetic counseling
Buyer Segments
Health systems and genetics clinics, Oncology practices, Women's health practices, Cardiology and neurology practices, Pediatric and rare disease programs
Assessment

Capability Axes

An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read

AI Capability
CC on AI CentralityArtificial intelligence is a feature layer on a product whose value stands without it. A learned component is a model whose parameters are estimated from data: machine learning, or a statistical model fitted to population data, including one then updated on the patient measurements. A fixed formula, a rule set, or a feedback controller that adjusts a dosing factor from the patient own readings is not one, however patient specific its output and whatever the vendor calls the adjustment.
Vendor Published

Machine learning is a feature layer inside a laboratory testing service whose value stands without it. What a clinician orders from Invitae is a sequencing test, interpreted by the laboratory's scientists under the Sherloc variant classification framework and returned with genetic counseling.

Two learned components are named on Invitae's tech and quality page. The Invitae Evidence Modeling platform trains gene specific models on curated evidence, keeps only those that pass accuracy thresholds, and feeds calibrated predictions into classification as one line of evidence among several; former Invitae scientists report that this evidence moved 42 percent of the variants it touched out of uncertain significance. Moon, a machine learning tool for exome analysis, weighs clinical and genetic information to rank the variants most likely to explain a patient's case. In both, the laboratory's scientists make the call.

BB on Autonomy and Oversight ModelThe oversight structure is described and one part is missing, commonly the threshold at which the system stops or what happens after it is wrong.
Vendor Published

The oversight structure is described, and what happens after a model supported call proves wrong is not. Model predictions are one line of evidence inside the standard classification framework, weighed by the laboratory's scientists rather than issued as a classification. Each model is gene specific, trained on input curated to a single evidence category, and used only if it clears an accuracy threshold, with calibrated scores mapped to defined evidence strengths. That is a stated rule for when the system may contribute.

The missing part is the response to error: how a model is withdrawn when it drifts, and how variants classified with its evidence are reviewed and reissued.

BB on Model and Technology TransparencyThe approach or the suppliers are named without the version and update discipline behind them. Naming a supplier is the entry to this band both here and on Model Supply Chain Disclosure, which ask different questions of the same disclosure: who receives the data, and what produces the output.
Vendor Published

The approach is named without version and update discipline. The preprint describes the Evidence Modeling platform's four design features: inputs curated to correspond to single evidence categories, gene specific model training and validation, accuracy threshold filtering, and calibrated pathogenicity scores mapped to classification categories. It names one component, a modified version of the SpliceAI splicing model, with code released publicly. Invitae also describes Moon, a machine learning tool that ranks exome variants, supported by Apollo, a gene and disease database kept current with text mining.

No inventory of the models in use, no version identifier on reports and no description of how retrained models are introduced is published.

BB on Model Supply Chain DisclosureSubstantial partial disclosure, or a chain that is structurally short: an in house build, a cleared model that cannot be quietly swapped, or a deployment where the transfer does not occur at all. Naming the model provider exits the band below into this one; the axis rises from here on the completeness of the party list and on the terms that govern data once it arrives.
Vendor Published

The chain is structurally short. The classification models are built in house on Invitae's curated evidence, including a modified version of the openly published SpliceAI model, and Moon and Apollo are Invitae's own tools, all running inside the laboratory's own interpretation process, so no outside model provider receives patient data for this step.

What is not published is the rest of the chain after the acquisition: which Labcorp systems and outside service providers handle sequence data and reports, and whether any processor sits between the laboratory and the record integrations. No subprocessor list is published.

BB on Clinical and Operational EvidenceNamed deployments with dated outcome figures and enough method to test them, or published research short of independent validation.
Vendor Published

Published research on the interpretation models, short of independent validation. A medRxiv preprint posted in February 2025 by fifteen authors, all former Invitae employees and most now at Labcorp, describes the Evidence Modeling platform applied to more than 800,000 variants across more than a million people. It reports that 42 percent of those variants would have been variants of uncertain significance without the model evidence, and that definitive classifications agreed with later ClinVar submissions more than 99 percent of the time, measured prospectively.

The work is not peer reviewed, and the concordance figure measures agreement with other laboratories' submissions rather than clinical outcomes. Invitae's tech and quality page adds an internal study in which Moon identified more than 97 percent of causative variants in 150 previously solved exome cases, a vendor figure with a one line method. Invitae also reports more than five million patients tested, which is scale rather than evidence of benefit.

CC on AI Safety and PHI StewardshipGeneral assurances of privacy and security that do not answer the questions artificial intelligence raises: what is retained, what reaches a model, and what happens to it there.
Vendor Published

Patient controls over de identified data are stated, and the questions machine learning raises are not answered. Invitae's privacy pages say its policies give patients rights beyond legal obligations over how their de identified data is shared, and that patients set preferences in the Invitae portal for certain research and commercial activities. Nothing published says whether patient results train the Evidence Modeling platform, how long samples and sequence data are kept, which de identification method applies, or whether preferences set before the acquisition carry over to Labcorp.

Safety engineering for the interpretation models, meaning how a model error would be detected and how affected reports are handled, is not published.

Regulatory and Compliance
BB on HIPAA and BAA PostureBusiness associate status is stated and supported by a substantive privacy document, with the agreement or its scope not fully published. For a vendor outside the United States, an equivalent regime documented to this depth grades here. A vendor whose product does not process protected health information grades here too when it says so plainly and explains the scope, with a service privacy document behind it: stating a position a buyer can rely on is the posture this axis grades, and the band above is closed to it because there is no agreement to publish.
Vendor Published

Invitae publishes a HIPAA Notice of Privacy Practices, effective 22 January 2021, covering how it uses and shares protected health information and patients' rights over it, and a privacy policy from Invitae Corporation, effective 25 January 2024, which says the two documents together govern patient information. As the testing laboratory, Invitae acts as a covered entity toward patients rather than as a business associate of the ordering health system.

Both documents predate Labcorp's acquisition, the site's legal footer is now Labcorp's, and neither document says which company holds patient records today or how they move between Invitae and Labcorp Genetics.

BB on Security Certifications and Trust CenterA recognized certification is named in the vendor own material without the artifact, or with a scope or renewal question the buyer has to raise. A recognized certification here is an audit of how the vendor operates security, such as SOC 2, HITRUST or ISO/IEC 27001. A certification has a scope and a clock, and both are part of this grade. A certification the vendor attaches to its data center, hosting facility or cloud provider, rather than presenting as its own, is the host's and does not count here.
Vendor Published

A recognized certification is named without the artifact. Invitae's licensing page states that it has achieved HITRUST CSF certification, and that its US laboratories are certified under CLIA and accredited by the College of American Pathologists, which cover testing quality rather than information security. The privacy policy carries a security measures section.

No certificate, assessment type, scope or date is published, no trust center or vulnerability disclosure route is named, and the page does not say whether the certification was renewed under Labcorp ownership. The systems behind it hold sequence data and results for more than five million patients and moved between companies in 2024.

CC on FDA and Regulatory StatusNo device claim is made and the product is scoped accordingly. Most administrative and operational products sit here and are not penalized for it, because this axis grades the appropriateness of the positioning rather than possession of a clearance.
Vendor Published

No device claim is made, and the models sit inside a laboratory's own interpretation process. The Evidence Modeling platform and Moon produce evidence that Invitae's scientists use to classify variants in tests the laboratory reports; neither is sold or delivered as software to anyone else. Invitae's licensing page states that its US laboratories are CLIA certified and CAP accredited, and no FDA clearance is claimed for any Invitae test or for the platform.

CC on AI Governance and Bias DisclosureResponsible artificial intelligence is committed to in policy language with no evaluation behind it. Most of the index sits here.
Vendor Published

A testing method is published and the subgroup results are not set out. The 2025 preprint describes how models are built and kept: curated inputs per evidence category, gene specific training and validation, accuracy threshold filtering and calibration. It also says that the platform has the potential to reduce the gap in uncertain results across race, ethnicity and ancestry groups, a known problem because reference data under represent many ancestries.

No results by ancestry group are presented on Invitae's pages, the preprint is not peer reviewed, and no governance process for changing or retiring models under Labcorp is described.

BB on AI Liability and RecourseA published falsifiable commitment, or a real correction route the affected person can exercise against the vendor. A published error rate with its method and denominator grades here. A statutory right that runs to the covered entity rather than to the vendor does not reach this band on its own: every other route here asks something of the vendor, and being located in a particular jurisdiction is not conduct.
Vendor Published

A vendor reported miss rate is published for one model, and reclassification may lead to an addended report; nothing stands behind a result. Invitae's tech and quality page reports that in an internal study of 150 previously solved exome cases, Moon identified more than 97 percent of causative variants, so about 3 percent were missed. Model evidence is weighed by the laboratory's scientists before a classification is reported, the report reaches a clinician with genetic counseling included, and when new evidence emerges Invitae says it reviews the classification and may issue an addended report to every tested person found to carry the variant.

The Moon study is internal and its method is described in one sentence. No error rate is published for model supported classifications, the addended report is not a commitment, and no warranty or remediation attaches to a result.

Integration and Deployment
BB on EHR and Interoperability DepthNamed systems with read access or one directional writing, or standards support with named deployments behind it.
Vendor Published

A named record system with a stated count of deployments, without named sites. Labcorp's July 2025 article on genetic testing integrations names Epic's Aura network for ordering and resulting Invitae tests and says Invitae and Labcorp teams have completed more than 400 customer record integrations, with results arriving securely in the record.

No health system is named as live, no other record system is named, and whether variant level results arrive as discrete data or as a report document is not described.

CC on Deployment Model and Data ResidencyA single hosted option with location implied rather than committed.
Vendor Published

A single laboratory service with location implied. Invitae tests and interprets in its own laboratory operation, now part of Labcorp, and returns results through its portal and record integrations. Nothing published says where sequence data and classification models are hosted, whether processing moved into Labcorp's systems after the acquisition, or where data rests.

Commercial
CC on Commercial TransparencyNo price is published and the posture is discoverable: a buyer can establish how the product is sold and what drives the cost before contacting the vendor. Most of the index sits here.
Vendor Published

No price is published, and how the testing is sold can be established. Invitae's provider billing questions describe billing per clinical area, payment options, a financial assistance program and cost estimates on request, and explain that patients and providers may receive bills from Invitae, from Labcorp Genetics or from both since the acquisition. Genetic counseling is included at no additional cost. The answers sit in an interactive page, and no patient pay figure, institutional rate or panel price is set out.

BB on Setting and Specialty CoverageCoverage is named with validation behind part of it.
Vendor Published

Coverage is named, with validation behind the model component. Invitae sells germline testing in six areas: oncology, women's health, pediatrics and rare disease, cardiology, neurology and genetic risk assessment. The Evidence Modeling platform is built gene by gene, with each model validated before use and discarded if it misses the accuracy threshold, so its coverage is the set of genes where a model passed, and the preprint reports concordance across the variants it was applied to.

Which genes and specialties carry validated models today is not listed on Invitae's pages.

Alternatives

Alternatives to Invitae

Other products that do the same kind of work as Invitae, and what each one does.

All Invitae alternatives, with prices →

Myriad Genetics is a genetic testing company in Salt Lake City, Utah, listed on NASDAQ as MYGN, that runs its tests in its own accredited laboratories.

Ambry Genetics is a genetic testing laboratory in Aliso Viejo, California, founded in 1999 and owned since 2025 by Tempus AI.

Rare disease genomic diagnosis company (NASDAQ: WGS) in Gaithersburg, Maryland, running exome and genome sequencing in its own accredited laboratory and interpreting it with automation, machine learning and clinical scientists over GeneDx Infinity, its dataset of prior cases.

Foundation Medicine, based in Boston and a member of the Roche Group, runs comprehensive genomic profiling for cancer in its own laboratories.

Genomics company in San Mateo, California, sequencing with its proprietary Exome+ assay in a CLIA certified, CAP accredited laboratory.

MyOme is a genomics company in Menlo Park, California, with a CLIA certified and CAP accredited laboratory, that sells whole genome screening built around integrated risk scores.

Comparisons

Compared With

Each comparison carries a written verdict, the buyer conditions that favor each vendor, and a graded side by side. Pairs that cross a category boundary are grouped separately, and their verdicts state where the boundary sits rather than manufacturing a head to head.

Commercial

Pricing

Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.

Entry Price Pricing Basis BAA Tier Implementation Source
Not published
Laboratory tests billed per clinical area to insurance, institutions or patients, with payment options, financial assistance and cost estimates (provider billing questions). Invitae acts as the covered entity laboratory under its own Notice of Privacy Practices (January 2021), which predates Labcorp's ownership. None published. Epic Aura ordering and results integration is offered. Vendor Published

Invitae's provider billing questions describe billing per clinical area, payment options, a financial assistance program and cost estimates, and say bills may come from Invitae, Labcorp Genetics or both since the Labcorp acquisition. Genetic counseling is included at no additional cost. No patient pay price, panel price or institutional rate is set out.

Invitae pricing in full →